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 Introduction 
 Gliomatosis cerebri (GC) is a glial tumor with a diffuse 
growth pattern consisting of exceptionally extensive in-
filtration of the central nervous system and with involve-
ment of at least 3 cerebral lobes  [1] . Its relationship with 
diffuse low-grade gliomas and highly infiltrative malig-
nant gliomas has remained unclear. No standard treat-
ment has been established. Due to the large extent of
tumor infiltration, the surgical options are limited. Ex-
tensive field radiotherapy can lead to clinical and radio-
logical stabilization or improvement, but requires high 
doses of 45 Gy and more and, therefore, carries the risk 
of neurotoxicity  [2, 3] . Efficacy data for primary chemo-
therapy are scarce and restricted to retrospective analy-
ses. After biopsy, temozolomide (TMZ) or PCV chemo-
therapy (procarbazine, CCNU, vincristine) lead to a me-
dian progression-free survival (mPFS) of 13–16 months 
and a median overall survival (mOS) of 25–27 months  [3, 
4] . In a small patient series, we had some indications for 
the efficacy of procarbazine and CCNU (PC) in patients 
with GC  [5] . On this basis, we continued to treat GC pa-
tients with PC. In most patients we omitted vincristine, 
since vincristine does not penetrate the blood brain bar-
rier  [6] . Here, we present the analysis of 12 patients who 
had received PC(V) chemotherapy in the pilot phase of a 
German multicenter trial. 
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 Abstract 
 Background: Gliomatosis cerebri (GC) is a diffuse infiltrating 
glial tumor with involvement of at least 3 cerebral lobes. 
There are only few data on the efficacy of initial chemother-
apy in patients with GC.  Patients and Methods: In 3 neu-
rooncological centers, patients with newly diagnosed GC 
who had received procarbazine (60 mg/m 2 , days 8–21/56) 
and CCNU (110 mg/m 2 , day 1/56) chemotherapy (PC) as initial 
treatment were analyzed for progression-free survival, over-
all survival and toxicity.  Results: Twelve patients (median 
age 46 years, range 27–72) were analyzed. The median pro-
gression-free survival and the median overall survival were 
16 and 37 months. Grade 3 or 4 hematotoxicity was observed 
in 3 of 12 patients (25%).  Conclusions: These data support 
the efficacy of PC chemotherapy in newly diagnosed GC. Ini-
tial PC chemotherapy should be considered as a treatment 
option and evaluated in larger clinical trials. 
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 Patients and Methods 
 For this analysis, patients with newly diagnosed GC who re-
ceived PC or PCV chemotherapy were retrieved from the institu-
tional data bases of the Department of Neurology, University of 
Tübingen, Tübingen, the Division of Clinical Neurooncology, 
Department of Neurology, University of Bonn, and the Depart-
ment of Neurosurgery, University of Mainz, Mainz, Germany. In-
formed consent for treatment was obtained from each patient be-
fore therapy. 
 GC was diagnosed according to the following criteria: (1) T 2 - 
or fluid-attenuated inversion recovery (FLAIR)-weighted MRI 
showing a diffuse infiltrative process involving more than 2 dif-
ferent lobes; (2) histological confirmation of a focal glial neoplas-
tic lesion. 
 The PC regimen was administered with 110 mg/m 2 CCNU on 
day 1 and with 60 mg/m 2 procarbazine on days 8–21 of 56-day 
courses. Tumor response was assessed by cranial MRI in subse-
quent courses according to the following criteria: a partial re-
sponse (PR) required a reduction in the contrast-enhancing tu-
mor mass by 50% and/or a reduction in the tumor mass on FLAIR 
sequences by at least 25% (without progression of the contrast-
enhancing tumor mass); progressive disease (PD) was diagnosed 
in case of a more than 25% increase in the contrast-enhancing 
tumor mass and/or tumor mass on FLAIR sequences. All other 
constellations between PR and PD were considered stable disease 
(SD). The diagnosis of PR and SD also required stable or improved 
neurological status. PFS and OS were calculated from the first 
dose of CCNU until progression or death, respectively. Survival 
data were analyzed according to the Kaplan-Meier method using 
the SPSS software version 12.0.1.
 Results 
 Patient and Treatment Characteristics 
 Twelve patients with newly diagnosed GC were treated 
with PC between December 2001 and December 2006. 
The patient characteristics are given in  table 1 . Ten pa-
tients had a biopsy only and 2 patients had a partial resec-
tion. Two patients had grade 2 oligodendroglioma and 10 
patients had grade 2 diffuse astrocytoma as histology of 
the location where the biopsy has been taken from. Nine 
patients were treated with PC and 3 patients were treated 
with PCV. A total of 43 courses of PC and 9 courses of 
PCV were administered. The median number of courses 
per patient was 4. One patient had only 1 course, and an-
other patient received the maximum of 7 courses.
 Efficacy and Toxicity of PC Chemotherapy 
 All patients were followed until tumor progression 
and death. SD was seen in 11 of 12 patients (92%) and 
prevailed in all of them for at least 2 months. There were 
no CR or PR. PFS and OS are shown in  figures 1 and  2 . 
mPFS was 16 months (95% CI 5–27;  fig. 1 ). The PFS rates 
at 12 and 24 months were 83 and 38%, respectively. mOS 
was 37 months (95% CI 33–41;  fig. 2 ). 
 Grade 3 or 4 hematologic toxicity was seen in 3 pa-
tients (25%) leading to a 25% reduction in the dose of PC. 
During procarbazine treatment, allergic skin reaction 
leading to treatment discontinuation occurred in 1 pa-
tient (8%). 
Table 1. Patient characteristics
Patients 12
PC 9 (75)
PCV 3 (25)
Demographic data  
Males 5 (42)
Females 7 (58)
Age, years
Median 46
Range 27–62
KPS
Median 80
Range 60–90
Treatment before inclusion  
Neurosurgery 12
Partial resection 2 (16)
Biopsy 10 (84)
PC(V) cycles  
Median 4
Range 1–7
Figures in parentheses are percentages.
KPS = Karnofsky performance status.
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 Fig. 1. PFS in the 12 patients with GC. 
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 Salvage Therapy 
 So far, 9 patients had recurrent disease and 8 of them 
received salvage therapy. Six of 8 patients were treated 
with involved-field radiotherapy (50.4–60 Gy) and 
showed an mPFS of 5 months. One patient with radio-
therapy and concurrent TMZ was stable for 3 months. 
Another patient received TMZ at first recurrence (200 
mg/m 2 , on day 5/28) and had SD for at least 5 months. 
Four patients who had radiotherapy at first relapse were 
evaluable for third-line treatment with TMZ (2 of them 
with a dose-intensive regimen). The median time to third 
progression was 2 months. 
 Discussion 
 This analysis suggests that PC chemotherapy may be 
effective in patients with newly diagnosed GC. PC leads 
to a comparably long median survival of 37 months. Al-
most 40% of patients showed long-term stabilization for 
more than 2 years upon PC therapy. Radiotherapy, which 
may be an alternative treatment option, had been less ac-
tive in previous studies, with median survival times rang-
ing between 11 and 24 months  [2, 7–9] . In the most com-
prehensive analysis of GC patients including 41 patients 
treated with radiotherapy alone, the retrospective com-
parison of patients receiving radiotherapy with patients 
not receiving radiotherapy did not reveal a prolongation 
of survival for those receiving radiotherapy, thus ques-
tioning its value  [10] . In our series, second-line radiother-
apy was also comparably ineffective with a short mPFS of 
5 months. Another problem with radiotherapy as the pri-
mary treatment strategy is the increased risk of leukoen-
cephalopathy with cognitive dysfunction due to the large-
field radiotherapy which is needed for this highly infiltra-
tive tumor  [11] .
 In contrast to radiotherapy, the comprehensive retro-
spective analysis provided by Taillibert et al.  [10] showed 
that the application of chemotherapy was a highly sig-
nificant prognostic factor. With primary TMZ chemo-
therapy, PFS was 13 months  [4] . Soffietti et al.  [12] showed 
a PFS of 9 months for 46 patients who received TMZ as 
primary or secondary therapy. Also, Levin et al.  [3] dem-
onstrated no significant difference between PCV- (n = 
17) and TMZ-treated (n = 46) patients in either mPFS (16 
months) or mOS (26 months). Our data add valuable in-
formation of 12 more patients and appear competitive 
with a PFS of 16 months and an mOS of 37 months. There 
was no strong selection of patients with good prognostic 
factors such as young age or high Karnofsky performance 
status in our case series. One could argue that our analy-
sis only comprises patients with local grade 2 histology 
which was a positive prognostic factor in some studies  [4, 
10] . However, in the study of Levin et al.  [3] , no correla-
tion between survival parameters and tumor grade was 
found. The comparably long OS in our cohort may be due 
to the high rate of patients receiving second-line therapy 
or even multiple salvage therapies. 
 In conclusion, the PC chemotherapy exhibits encour-
aging efficacy in newly diagnosed GC. Initial PC chemo-
therapy should be considered as a treatment option and 
evaluated in larger clinical trials. A German multicenter 
trial (NOA-05) investigating this concept is already re-
cruiting.
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 Fig. 2. OS in the 12 patients with GC. 
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